Nuvectis Pharma price target raised to $33 from $20 at Roth Capital

Roth Capital raised the firm’s price target on Nuvectis Pharma (NVCT) to $33 from $20 and keeps a Buy rating on the shares. The company “significantly improved” its clinical-stage pipeline by licensing ex-China/India/select Southeast Asian country rights to CFB inhibitor NXP100 and ex-China rights to BRAF inhibitor NXP200 from Haisco Pharmaceutical, says the analyst, who updated the firm’s model for the acquisitions as well as the recent “substantial” capital raise of $93M in net proceeds.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on NVCT:

Disclaimer & DisclosureReport an Issue